We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3!
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
www.targetedonc.com
September 25, 2026 at 10:56 AM
We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3!
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape? Watch the discussion below. 👇
sohoinsider.com/roundtable-d...
sohoinsider.com/roundtable-d...
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
The roundtable panelists discuss where CELMoDs, including mezigdomide and iberdomide, fit in the multiple myeloma treatment landscape. The panel evaluates the distinct toxicity profiles of these…
sohoinsider.com
September 19, 2026 at 9:30 PM
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape? Watch the discussion below. 👇
sohoinsider.com/roundtable-d...
sohoinsider.com/roundtable-d...
CELMoDs in multiple myeloma: a decade of progress. Dr. Ajay Nooka reviews the clinical development of iberdomide and mezigdomide for #SOHO2026
Read more here: sohoinsider.com/news/celmods...
Read more here: sohoinsider.com/news/celmods...
CELMoDs in multiple myeloma: a decade of progress
The first- and second-generation immunomodulatory drugs (IMiDs) have fundamentally transformed the treatment landscape of multiple myeloma (MM) over the past two decades. Lenalidomide combinations…
sohoinsider.com
September 12, 2026 at 3:26 PM
CELMoDs in multiple myeloma: a decade of progress. Dr. Ajay Nooka reviews the clinical development of iberdomide and mezigdomide for #SOHO2026
Read more here: sohoinsider.com/news/celmods...
Read more here: sohoinsider.com/news/celmods...
🎙️ Just published a new episode of Blood Podcast: Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM. Have a listen:
Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM
In this week's episode, Blood editor Laurie Sehn interviews Drs....
bloodpodcast.transistor.fm
August 27, 2026 at 6:24 PM
🎙️ Just published a new episode of Blood Podcast: Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM. Have a listen:
At #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety.
August 5, 2026 at 4:01 PM
At #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety.
Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight.
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
July 20, 2026 at 6:47 PM
Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight.
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
Article link 👇
#MultipleMyeloma #Oncology #ClinicalTrials
[Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
arc-codex.com
July 19, 2026 at 5:49 AM
[Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
🌟 This week's #OncFive 🌟:
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 7/12 | OncLive
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
www.onclive.com
July 18, 2026 at 7:24 PM
🌟 This week's #OncFive 🌟:
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
🎗️ FDA clears gedatolisib in select PIK3CA WT mBC
🧬 Selpercatinib full approval in RET fusion+ tumors
🚫 3rd CRL for rivoceranib/camrelizumab in 1L HCC
🩸 NDA accepted for mezigdomide combo in r/r myeloma
🟡 Fast track for SOT109 in CRC
🔗: www.onclive.com/view/the-onc...
Feed: "SOHO Insider"
By: Leah Sherwood on Tuesday, July 14, 2026
By: Leah Sherwood on Tuesday, July 14, 2026
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
The US FDA accepted an NDA for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
sohoinsider.com
July 14, 2026 at 9:02 AM
Feed: "SOHO Insider"
By: Leah Sherwood on Tuesday, July 14, 2026
By: Leah Sherwood on Tuesday, July 14, 2026
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
sohoinsider.com/news/fda-acc...
sohoinsider.com/news/fda-acc...
FDA accepts NDA for mezigdomide combo in R/R myeloma
The US FDA accepted an NDA for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
sohoinsider.com
July 14, 2026 at 2:13 AM
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
sohoinsider.com/news/fda-acc...
sohoinsider.com/news/fda-acc...
Don't miss our full discussion on CELMoDs in myeloma. Watch here: youtu.be/OCko_j9ohrs?...
Where do CELMoDs, including mezigdomide and iberdomide, fit in the treatment landscape?
YouTube video by SOHO Insider
youtu.be
July 13, 2026 at 3:20 PM
Don't miss our full discussion on CELMoDs in myeloma. Watch here: youtu.be/OCko_j9ohrs?...
The @fda.gov has accepted an NDA seeking the approval of mezigdomide plus carfilzomib/dexamethasone for relapsed/refractory multiple myeloma.
Read more on the acceptance and dive into the SUCCESSOR-2 data supporting the application #mmsm #oncology www.onclive.com/view/fda-acc...
Read more on the acceptance and dive into the SUCCESSOR-2 data supporting the application #mmsm #oncology www.onclive.com/view/fda-acc...
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma | OncLive
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
www.onclive.com
July 13, 2026 at 1:28 PM
The @fda.gov has accepted an NDA seeking the approval of mezigdomide plus carfilzomib/dexamethasone for relapsed/refractory multiple myeloma.
Read more on the acceptance and dive into the SUCCESSOR-2 data supporting the application #mmsm #oncology www.onclive.com/view/fda-acc...
Read more on the acceptance and dive into the SUCCESSOR-2 data supporting the application #mmsm #oncology www.onclive.com/view/fda-acc...
#BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
https://www.stocktitan.net/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-pkj5dk39tnjc.html
https://www.stocktitan.net/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-pkj5dk39tnjc.html
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, for the treatment of multiple myeloma.
www.stocktitan.net
July 13, 2026 at 10:59 AM
#BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
https://www.stocktitan.net/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-pkj5dk39tnjc.html
https://www.stocktitan.net/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-pkj5dk39tnjc.html
Feed: "SOHO Insider"
By: SOHO Insider Editors on Monday, July 6, 2026
By: SOHO Insider Editors on Monday, July 6, 2026
How to sequence mezigdomide-based therapy in myeloma?
What is mezigdomide's position in the multiple myeloma landscape? The myeloma panel discusses in this video roundtable from EHA 2026.
sohoinsider.com
July 7, 2026 at 8:47 PM
Feed: "SOHO Insider"
By: SOHO Insider Editors on Monday, July 6, 2026
By: SOHO Insider Editors on Monday, July 6, 2026
Feed: "SOHO Insider"
By: SOHO Insider Editors on Thursday, July 2, 2026
By: SOHO Insider Editors on Thursday, July 2, 2026
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
At this EHA 2026 roundtable, panelists discuss where CELMoDs, mezigdomide and iberdomide, fit in the multiple myeloma treatment landscape.
sohoinsider.com
July 2, 2026 at 7:18 PM
Feed: "SOHO Insider"
By: SOHO Insider Editors on Thursday, July 2, 2026
By: SOHO Insider Editors on Thursday, July 2, 2026
Mezigdomide + carfilzomib + dexamethasone regimen reduces disease progression in r/r MM, phase III trial finds
https://cancerletter.com/clinical-roundup/20260626_9c/
https://cancerletter.com/clinical-roundup/20260626_9c/
Mezigdomide + carfilzomib + dexamethasone regimen reduces disease progression in r/r MM, phase III trial finds - The Cancer Letter
Mezigdomide, carfilzomib, and dexamethasone demonstrated a >50% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone, according to the results of the SUCCESSOR-2 phase III trial. To access this subscriber-only content please log in or subscribe.If your institution has a site license, […]
cancerletter.com
July 2, 2026 at 3:00 PM
Mezigdomide + carfilzomib + dexamethasone regimen reduces disease progression in r/r MM, phase III trial finds
https://cancerletter.com/clinical-roundup/20260626_9c/
https://cancerletter.com/clinical-roundup/20260626_9c/
#CELMoDs are CRBN molecular glues overcoming resistance in multiple myeloma where #IMiDs fail. Reprogram CRBN→degrade IKZF1/IKZF3→tumor suppression + immune activation. Key Pipeline Compounds:
• #Iberdomide — Phase III MM
• #Mezigdomide — Phase III RRMM
• #Golcadomide — Phase II/III B-cell lymphoma
• #Iberdomide — Phase III MM
• #Mezigdomide — Phase III RRMM
• #Golcadomide — Phase II/III B-cell lymphoma
July 2, 2026 at 12:02 PM
#CELMoDs are CRBN molecular glues overcoming resistance in multiple myeloma where #IMiDs fail. Reprogram CRBN→degrade IKZF1/IKZF3→tumor suppression + immune activation. Key Pipeline Compounds:
• #Iberdomide — Phase III MM
• #Mezigdomide — Phase III RRMM
• #Golcadomide — Phase II/III B-cell lymphoma
• #Iberdomide — Phase III MM
• #Mezigdomide — Phase III RRMM
• #Golcadomide — Phase II/III B-cell lymphoma
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. www.thelancet.com/journals/lan...
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled tr...
Mezigdomide–carfilzomib–dexamethasone provided a significant PFS benefit compared
with carfilzomib–dexamethasone alone, with higher rates of grade 3 or 4 adverse events,
including infections, which we...
www.thelancet.com
June 19, 2026 at 9:39 AM
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. www.thelancet.com/journals/lan...
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Wednesday, June 17, 2026
By: GlobalData Healthcare on Wednesday, June 17, 2026
EHA26: BMS touts positive multiple myeloma data for two pipeline candidates
BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference.
www.clinicaltrialsarena.com
June 18, 2026 at 10:34 AM
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Wednesday, June 17, 2026
By: GlobalData Healthcare on Wednesday, June 17, 2026
Tremendous!
"Mezigdomide worked by attaching to a specific protein in the body. It acted like a magnet, attracting disease-causing proteins that were vital for survival of multiple myeloma cells and degrading them."
"Mezigdomide worked by attaching to a specific protein in the body. It acted like a magnet, attracting disease-causing proteins that were vital for survival of multiple myeloma cells and degrading them."
June 6, 2026 at 6:17 AM
Tremendous!
"Mezigdomide worked by attaching to a specific protein in the body. It acted like a magnet, attracting disease-causing proteins that were vital for survival of multiple myeloma cells and degrading them."
"Mezigdomide worked by attaching to a specific protein in the body. It acted like a magnet, attracting disease-causing proteins that were vital for survival of multiple myeloma cells and degrading them."
Could a new standard of care be emerging for R/R #multiplemyeloma? At #ASCO26, Dr Richardson highlights phase III SUCCESSOR-2 data showing that mezigdomide plus carfilzomib and dexamethasone significantly improved progression-free survival. ecancer.org/en/video/129...
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma - ecancer
At ASCO 2026, Dr Paul Richardson talks to ecancer about results from the phase III SUCCESSOR-2 study evaluating mezigdomide plus carfilzomib and dexamethasone i
ecancer.org
June 1, 2026 at 3:29 PM
Could a new standard of care be emerging for R/R #multiplemyeloma? At #ASCO26, Dr Richardson highlights phase III SUCCESSOR-2 data showing that mezigdomide plus carfilzomib and dexamethasone significantly improved progression-free survival. ecancer.org/en/video/129...
🆕 #ASCO26! 🚨 The Phase 3 SUCCESSOR-2 trial shows that adding oral mezigdomide to Kd nearly doubles progression-free survival in RRMM.
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
Mezigdomide Shows Survival Benefit in RRMM - Hematology Advisor
Researchers compared combination mezigdomide with carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with RRMM.
bit.ly
May 31, 2026 at 8:45 PM
🆕 #ASCO26! 🚨 The Phase 3 SUCCESSOR-2 trial shows that adding oral mezigdomide to Kd nearly doubles progression-free survival in RRMM.
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
📈 Median PFS: 18.0 mos vs 8.3 mos
📉 52% reduction in risk of progression/death (HR 0.48)
A major leap for triple-class exposed patients. 🧬
🔗 https://bit.ly/4u7KJhA
ASCO: Will New Drugs Demonstrate Benefits Over Generics? worldofdtcmarketing.com/asco-will-ne...
ASCO: Will New Drugs Demonstrate Benefits Over Generics?
At Asco, the data looks strong for BMS's Mezigdomide. It recently showed a 52% reduction in the risk of progression or death in relapsed/refractory multiple myeloma, extending median progression-free ...
worldofdtcmarketing.com
May 31, 2026 at 9:31 AM
ASCO: Will New Drugs Demonstrate Benefits Over Generics? worldofdtcmarketing.com/asco-will-ne...